SYDNEY, AUSTRALIA--(Marketwired - Jun 19, 2014) - Prima BioMed Ltd (
Dr. Heidi Gray, lead investigator, will deliver a presentation on final progression free survival (PFS) and interim overall survival (OS) data for Epithelial Ovarian Cancer patients in First or Second Remission (the CAN-003 protocol). As outlined in her presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May and as previously announced, Dr Gray will highlight the positive trends demonstrated in PFS and OS for CVac in the second remission patient population.
The following are specific details regarding Prima's presentation.
Event: 2014 WAGO Annual Meeting
Date: Thursday, June 26, 2014
Time: 10:35am - 10:45am
Location: Ritz Carlton Lake Tahoe, Salon III
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
Contact Information:
For further information please contact:
USA Investor/Media:
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Australia Investor/Media:
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52